rimonabant


Also found in: Wikipedia.

rimonabant

A selective cannabinoid-1 receptor blocker that has been shown to reduce body weight and the risk of cardiovascular disease in obese people. The drug has been shown capable of achieving substantial weight loss and reducing cardiovascular risk factors. It has aroused excitement among drug manufacturers who hope it may prove effective in the control of smoking as well as excessive calorie and alcohol intake.
References in periodicals archive ?
They were given 5mg or 20mg of rimonabant, or a dummy pill once daily in addition to a calorie-controlled diet.
Sanofi-Aventis might have a chance at getting approval for its obesity drug Accomplia (rimonabant) with data it's already compiled.
But Sanofi is not completely through with rimonabant. A phase III trial of the drug, marketed in Europe as Acomplia, is expected to report data in the second half of 2009.
The European Medicines Agency warned that rimonabant, brand name Acomplia, could cause "psychiatric side effects".
Shortly after an expert panel voted unanimously against approving rimonabant (Zimulti), Sanofi Aventis withdrew its new drug application for this weight-loss drug from the Food and Drug Administration.
The closest thing to a clinical trial in this context was a preliminary experiment with rimonabant (Acomplia), a synthetic cannabinoid drug recently introduced for modulation of appetite and treatment of obesity.
MUNICH -- The investigational drug rimonabant, first in a new class of agents known as selective endocannabinoid type 1 receptor blockers, is looking more and more like the real deal: a potential blockbuster drug causing sustained weight loss in the obese, reversal of the metabolic syndrome, an improved cardiovascular risk profile, and increased success in smoking cessation.
CRB-4001 was specifically designed to eliminate blood-brain barrier penetration and brain CB1 receptor occupancy that mediate the neuropsychiatric issues associated with first-generation CB1 inverse agonists such as rimonabant. Corbus expects to initiate a Phase 1 study for CRB-4001 in 2019.
To date, 2 RCTs comparing rimonabant, a CB1 inverse agonist, with placebo (PLB) in patients with schizophrenia have failed to demonstrate any benefit for psychotic symptoms or cognitive deficits.
The prescription drugs they sold included Clenbuteral, which bodybuilders use to burn fat; drugs used to treat erectile dysfunction; the fertility drug Clomid; the anti-obesity drug rimonabant; and four breast-cancer drugs, including tamoxifen.